NTS-WBRT in Brain Metastases
Phase 2 Recruiting
41 enrolled
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Phase 2 Recruiting
104 enrolled
MOMENTUM-1
Phase 2 Recruiting
153 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
Phase 2 Recruiting
316 enrolled
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Phase 2 Recruiting
180 enrolled
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Phase 2 Recruiting
162 enrolled
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Phase 2 Recruiting
37 enrolled
MK-6482-015
Phase 2 Recruiting
322 enrolled 3 FDA
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Phase 2 Recruiting
90 enrolled
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 Recruiting
30 enrolled
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Phase 2 Recruiting
20 enrolled
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Phase 2 Recruiting
120 enrolled
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2 Recruiting
38 enrolled
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2 Recruiting
38 enrolled
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 Recruiting
40 enrolled
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Phase 2 Recruiting
36 enrolled
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
Phase 2 Recruiting
28 enrolled
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 Recruiting
124 enrolled
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 Recruiting
70 enrolled
PRISM
Phase 2 Recruiting
38 enrolled
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 Recruiting
254 enrolled
GABLE
Phase 2 Recruiting
100 enrolled
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase 2 Recruiting
200 enrolled
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase 2 Recruiting
94 enrolled
TUVASTRAT
Phase 2 Recruiting
56 enrolled
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase 2 Recruiting
130 enrolled
Sacituzumab Govitecan in Recurrent Glioblastoma
Phase 2 Recruiting
32 enrolled
MIRAGE
Phase 2 Recruiting
104 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Phase 2 Recruiting
60 enrolled
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Phase 2 Recruiting
23 enrolled
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 Recruiting
62 enrolled
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 Recruiting
52 enrolled
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Phase 2 Recruiting
60 enrolled
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 Recruiting
120 enrolled
INSPIRE-NF1
Phase 2 Recruiting
25 enrolled
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Phase 2 Recruiting
150 enrolled
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Phase 2 Recruiting
60 enrolled
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Phase 2 Recruiting
103 enrolled
SUR-CAN
Phase 2 Recruiting
88 enrolled
TEMPO
Phase 2 Recruiting
118 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2 Recruiting
286 enrolled
Abemaciclib in Newly Diagnosed Meningioma Patients
Phase 2 Recruiting
72 enrolled
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 Recruiting
45 enrolled
NF114
Phase 2 Recruiting
200 enrolled
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Phase 2 Recruiting
75 enrolled
PNOC029
Phase 2 Recruiting
57 enrolled
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Phase 2 Recruiting
155 enrolled